Conditions: Postmenopausal Osteoporosis
Keywords: Osteoporosis, Osteoporosis-Postmenopausal, Bone Diseases-Metabolic, Bone Diseases, Musculoskeletal Diseases
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 7180
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine if treatment with romosozumab is effective in preventing fractures in women with postmenopausal osteoporosis

Detailed description:

Arms:
arm 1: Participants received 210 mg romosozumab subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months. arm 2: Participants received placebo subcutaneous injections once a month for 12 months, followed by 60 mg denosumab subcutaneously once every 6 months for 24 months.

Interventions: intervention 1: Romosozumab intervention 2: Placebo intervention 3: Denosumab
Intervention descriptions: intervention 1: Administered by subcutaneous injection once a month (QM) intervention 2: Administered by subcutaneous injection once a month (QM) intervention 3: Administered by subcutaneous injection once every 6 months (Q6M)

Protocol document: